Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Multiple of Ten Bearish | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Multiple of Ten Bearish | Other | -4.11% | |
| Inside Day | Range Contraction | -4.11% | |
| Lower Bollinger Band Touch | Weakness | -4.11% | |
| New Downtrend | Bearish | -2.05% | |
| 50 DMA Support | Bullish | -2.05% | |
| Wide Range Bar | Range Expansion | -2.05% | |
| Multiple of Ten Bearish | Other | -2.05% | |
| Lower Bollinger Band Touch | Weakness | -2.05% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Inside Day | about 8 hours ago |
| Lower Bollinger Band Support | about 10 hours ago |
| Fell Below Lower Bollinger Band | about 10 hours ago |
| Down 3% | about 10 hours ago |
| 60 Minute Opening Range Breakdown | about 11 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/06/2023
Apellis Pharmaceuticals, Inc. Description
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Organ Systems Eye Inflammatory Diseases Macular Degeneration Pulmonary Disease Chronic Obstructive Pulmonary Disease Hemoglobin Autoimmune And Inflammatory Disease Complement System Acquired Hemolytic Anemia Copd Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Intravitreal Administration
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 94.75 |
| 52 Week Low | 19.8301 |
| Average Volume | 4,700,704 |
| 200-Day Moving Average | 61.84 |
| 50-Day Moving Average | 36.42 |
| 20-Day Moving Average | 43.27 |
| 10-Day Moving Average | 43.74 |
| Average True Range | 3.22 |
| RSI (14) | 39.39 |
| ADX | 25.64 |
| +DI | 18.68 |
| -DI | 33.01 |
| Chandelier Exit (Long, 3 ATRs) | 41.87 |
| Chandelier Exit (Short, 3 ATRs) | 44.73 |
| Upper Bollinger Bands | 48.75 |
| Lower Bollinger Band | 37.78 |
| Percent B (%b) | 0.02 |
| BandWidth | 25.36 |
| MACD Line | 0.03 |
| MACD Signal Line | 0.86 |
| MACD Histogram | -0.8315 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 41.78 | ||||
| Resistance 3 (R3) | 42.15 | 41.29 | 41.15 | ||
| Resistance 2 (R2) | 41.29 | 40.34 | 41.10 | 40.94 | |
| Resistance 1 (R1) | 39.66 | 39.75 | 39.23 | 39.29 | 40.74 |
| Pivot Point | 38.80 | 38.80 | 38.58 | 38.61 | 38.80 |
| Support 1 (S1) | 37.17 | 37.85 | 36.74 | 36.80 | 35.34 |
| Support 2 (S2) | 36.31 | 37.26 | 36.12 | 35.14 | |
| Support 3 (S3) | 34.68 | 36.31 | 34.93 | ||
| Support 4 (S4) | 34.31 |
